Prospective Cohort for Adult Hemophagocytosis

This prospective cohort study enrolls adult patients who show signs of hemophagocytic lymphohistiocytosis (HLH), a rare and potentially life-threatening condition where the immune system becomes dangerously overactivated, causing severe inflammation and damage to organs. The study aims to better characterize HLH in adults by carefully tracking clinical features, lab findings, and responses to immunosuppressive or chemotherapy treatment over time. Eligible participants are adults over 18 who meet at least partial diagnostic criteria for HLH — either confirmed tissue evidence of hemophagocytosis or at least 3 of the 8 standard HLH diagnostic criteria — and provide written informed consent. Participation involves regular monitoring by study physicians, laboratory evaluations, and treatment according to the study protocol for HLH. This summary was prepared using AI to help patients understand the study in plain language.